Research progress of HGF/c-Met signaling pathway in oral squamous cell carcinoma

Research progress of HGF/c-Met signaling pathway in oral squamous cell carcinoma

Oral squamous cell carcinoma (OSCC) is a malignant tumor that seriously threatens human health. Its typical biological characteristics include strong local invasiveness, high lymph node metastasis rate, and high recurrence rate after treatment. Hepatocyte growth factor (HGF), cellular-mesenchymal to...

Full description

Saved in:

Bibliographic Details
Main Author:	SHI Jiafan, GONG Lingling, SUN Mingze, LIU Lulu, ZHANG Huilin, LI Ming
Format:	Article
Language:	zho
Published:	Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases 2025-08-01
Series:	口腔疾病防治
Subjects:	oral squamous cell carcinoma\|hepatocyte growth factor\|cellular-mesenchymal to epithelial transition factor\|mechanism\|phosphatidylinositide 3-kinases\|protein kinases b\|epidermal growth factor receptor\|targeted therapy\|monoclonal antibodies\|tyrosine kinase inhibitor
Online Access:	https://www.kqjbfz.com/fileup/2096-1456/PDF/1754449152045-978652041.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)
by: Ma. Carmela P. Dela Cruz, et al.
Published: (2025-05-01)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
by: Vishwanath Sathyanarayanan, et al.
Published: (2014-01-01)

MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation
by: Célia Guérin, et al.
Published: (2025-08-01)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
by: Jiannong Li, et al.
Published: (2013-11-01)

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
by: Luo FX, et al.
Published: (2025-04-01)

Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients
by: Xin Nie, et al.
Published: (2025-03-01)

ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma
by: Fangfang Yang, et al.
Published: (2025-05-01)

Research Status and Progress of Third-generation EGFR-TKIs  in Elderly Patients with Non-small Cell Lung Cancer
by: Xue CHEN, et al.
Published: (2025-05-01)

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

KEAP1-NRF2 Pathway as a Novel Therapeutic Target for EGFR-Mutant Non-small Cell Lung Cancer
by: Jae-Sun Choi, et al.
Published: (2025-01-01)

Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer
by: Wenjun Ren, et al.
Published: (2025-05-01)

Ponatinib-induced eruptive squamous cell carcinomas
by: Gabrielle Moore, MBE, MSc, et al.
Published: (2025-08-01)

Spread through air spaces may predict early progression after salvage surgery for EGFR-mutant advanced lung adenocarcinoma treated with targeted therapy
by: Yu-Wei Liu, et al.
Published: (2025-02-01)

Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
by: Zong-Han Yao, et al.
Published: (2025-08-01)

Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report
by: Caijiu Deng, et al.
Published: (2025-04-01)

New Paradigm in Treating Cancer: Right on Target
by: Noorwati Sutandyo
Published: (2016-09-01)

New Paradigm in Treating Cancer: Right on Target
by: Noorwati Sutandyo
Published: (2016-09-01)

Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs
by: Junmin Li, et al.
Published: (2025-07-01)

Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer
by: Kimio Yonesaka, et al.
Published: (2025-03-01)

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
by: Cristina Maria Failla, et al.
Published: (2024-12-01)

Angiogenic Factors in Cord Blood of Preterm Infants Predicts Subsequently Developing Bronchopulmonary Dysplasia
by: Wen-Chien Yang, et al.
Published: (2015-12-01)

The Difficulties of Differential Diagnosis of the Bronchial Obstruction Syndrome
by: I. V. Demko, et al.
Published: (2021-08-01)

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2024-01-01)

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients
by: Piyada Sitthideatphaiboon, et al.
Published: (2025-01-01)

Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2
by: Shaoyi Cao, et al.
Published: (2024-12-01)

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
by: Han X, et al.
Published: (2024-11-01)

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study
by: Yaxiong Zhang, et al.
Published: (2025-07-01)

The expression and clinical significance of PTK7 in oral squamous cell carcinoma
by: JIA Guodong, et al.
Published: (2023-04-01)

Risk Stratification and Adjuvant Chemotherapy for High‐Risk Stage IA Lung Adenocarcinoma: The Unmet Needs
by: Chen Shen, et al.
Published: (2025-01-01)

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01)

Vitamin K supports TGF-β1 depended in vitro human Langerhans cell differentiation and function via Axl
by: Thomas Bauer, et al.
Published: (2025-02-01)

A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database
by: Zongwei Tang, et al.
Published: (2025-07-01)

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review
by: Chuang Yang, et al.
Published: (2025-08-01)

Mesenchymal stem cell-derived exosomes improve vascular remodeling by inhibiting EGFR/ErbB2 heterodimerization in hypoxic pulmonary hypertension
by: Yao-Xin Chen, et al.
Published: (2025-07-01)

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration
by: Huijing Feng, et al.
Published: (2025-03-01)

Palmitoylation Transduces the Regulation of Epidermal Growth Factor to Organic Anion Transporter 3
by: Zhou Yu, et al.
Published: (2025-06-01)

Effect of modulating the extracellular matrix cross linkage by genipin on tumor cell resistance and survival in thioacetamide-induced hepatocellular carcinoma in rats
by: Hanan M. Hassan, et al.
Published: (2025-07-01)

Luteolin attenuates inflammation and apoptosis in LPS-induced ALI mice by activating the HGF/c-Met pathway
by: Jihong Bi, et al.
Published: (2025-07-01)

Novel Insights Into Receptor Tyrosine Kinases in Pulmonary Arterial Hypertension
by: Wenze Wu, et al.
Published: (2025-08-01)

Functional Characterization of the SHIP1-Domains Regarding Their Contribution to Inositol 5-Phosphatase Activity
by: Spike Murphy Müller, et al.
Published: (2025-01-01)